Data for ZYN002 CBD Gel Phase 1 Trial in Epilepsy, other Disease Released by Zynerba
News
Zynerba Pharmaceuticals, Inc. recently reported positive top line data from its Phase 1 ascending dose study of ZYN002, the first non-psychoactive cannabinoid, formulated as a gel for transdermal delivery for patients ... Read more